Anticoagulant News and Research

RSS

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

Clinical testing service for safer dosing of warfarin

Machaon Diagnostics, California's only independent laboratory for testing bleeding and clotting disorders has launched a clinical testing service for patients that have been prescribed warfarin. Warfarin, also known as Coumadin, Jantoven or warfarin sodium, is a potent 'blood thinner' or anticoagulant.

8 Apr 2010

Results of M118 EMINENCE clinical trial published in Circulation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation.

8 Apr 2010

FamilyCord acquires assets of Vista Cord

FamilyCord, a subsidiary of California Cryobank, announced the recent asset acquisition of Vista Cord, a regional cord blood bank primarily servicing the southern US states. In conjunction with the FDA and cryogenic transport experts, FamilyCord has successfully relocated all cord blood units to their state-of-the-art facility in Los Angeles.

6 Apr 2010

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches and widespread uptake of novel oral anticoagulants will drive the venous thromboembolism drug market to nearly double from $2.9 billion in 2008 to more than $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

31 Mar 2010

FDA grants tentative approval for Teva Pharmaceutical Industries' generic Argatroban ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of the anticoagulant, Argatroban® injection, 100mg/mL.

26 Mar 2010

AGA Medical gets IDE approval to evaluate AMPLATZER Cardiac Plug

AGA Medical Holdings, Inc. today announced it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to evaluate the safety and efficacy of its AMPLATZER® Cardiac Plug, or ACP, to close the left atrial appendage.

25 Mar 2010

Study: Older adults with chronic illness often struggle to manage several prescribed drugs at a time

People with chronic illness often struggle to manage several prescribed drugs at a time. It's overwhelming when the vials, bottles and inhalers bulge from your medicine cabinet and you're confused about which drug is which, or when to take what.

20 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

Iverson Genetic Diagnostics, Inc. today announced that they will conduct a WARFARIN clinical study to assess the efficacy of gene-based testing prior to initiating warfarin anticoagulation therapy to reduce the incidence of bleeding and thromboembolic events.

16 Mar 2010

RE-LY study: Dabigatran etexilate shows greater reductions in stroke compared to warfarin

Data presented today at the 59th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate compared to the current standard of care, warfarin, irrespective of a patient’s risk profile for stroke.

16 Mar 2010

EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin

Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.

16 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Domiciliary parenteral nutrition helps children with serious intestinal problems live more normally

Children with serious intestinal problems have to be fed intravenously. There moreover, exist systems that enable intravenous feeding to be carried out at home. Mr I-aki Irastorza, paediatrician at the Cruces hospital in Bilbao, spent some 15 years analysing how serious intestinal problems in children were treated at the Great Ormond Street Children's Hospital in London. With the gathered data he has presented a highly novel PhD thesis at the University of the Basque Country.

9 Mar 2010

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.

5 Mar 2010

DVT Awareness In Motion: Educational program on the importance of preventative care for DVT

The Coalition to Prevent Deep-Vein Thrombosis moves into action with the seventh national DVT Awareness Month by introducing DVT Awareness In Motion, a educational program designed to drive dialogue about the importance of preventative care for DVT via simple movements – that can be done anywhere and anytime.

4 Mar 2010

FamilyCord introduces start-of-the-art collection kit for cord blood banking industry

FamilyCord, a subsidiary of California Cryobank, is leading the charge in the private cord blood banking industry for safer, more effective collection kits. FamilyCord's start-of-the-art collection kit is redefining the scientific standards for collection and transport employed by the cord blood banking industry.

2 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Anticoagulant News and Research

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

Clinical testing service for safer dosing of warfarin

Results of M118 EMINENCE clinical trial published in Circulation

FamilyCord acquires assets of Vista Cord

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

FDA grants tentative approval for Teva Pharmaceutical Industries' generic Argatroban ANDA

AGA Medical gets IDE approval to evaluate AMPLATZER Cardiac Plug

Study: Older adults with chronic illness often struggle to manage several prescribed drugs at a time

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

Pathway Genomics' personal Genetic Health Report now available

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

RE-LY study: Dabigatran etexilate shows greater reductions in stroke compared to warfarin

EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin

Regado Biosciences announces first successful subcutaneous application of an aptamer

Domiciliary parenteral nutrition helps children with serious intestinal problems live more normally

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

DVT Awareness In Motion: Educational program on the importance of preventative care for DVT

FamilyCord introduces start-of-the-art collection kit for cord blood banking industry

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News